- Conditions
- Contrast Enhancement in Magnetic Resonance Imaging, Children
- Interventions
- Gadoquatrane (BAY1747846)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 0 Years to 17 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Indian Wells, California • Kansas City, Missouri • Charleston, South Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Contrast Enhancement in Magnetic Resonance Imaging, Central Nervous System Pathology
- Interventions
- Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine, Gadoteridol
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 8
- States / cities
- Indian Wells, California • Orange, California • Miami, Florida + 5 more
- Conditions
- Central Nervous System Pathology
- Interventions
- Gadoquatrane (BAY1747846), Gadobutrol (Gadovist/Gadavist)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Iowa City, Iowa • Hershey, Pennsylvania
- Conditions
- Contrast Enhancement in Magnetic Resonance Imaging, Non-central Nervous System Pathology
- Interventions
- Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine, Gadoteridol
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Indian Wells, California • Orange, California + 6 more